Ravoxertinib

(Synonyms: GDC-0994)
52 Cited Publications
고객리뷰

Based on 52 publication(s) in Google Scholar

Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

  • Purity : 99.74%
  • CAS No.: 1453848-26-4
  • 화학식: C21H18ClFN6O2
  • 분자량:440.86
  • 보관:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 2 years , -20°C, 1 year
  • Biological Activity
  • Chemical Information
  • 용액&용해도
  • Protocol
  • 순도&문서
  • References
  • Help & FAQs

Publications Citing Use of MedChemExpress (MCE) Ravoxertinib

More
Customer Validation & Images
RT-PCRCell Proliferation/Viability AssayIP
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • RT-PCR
  • IP
  • RT-PCR
  • RT-PCR

All ERK Isoforms

More
MOQ
Minimum order quantity
100 mg

견적 받기 해외재고보유

Other size
견적 받기
Please select quantity
Amount: USD 0.00